News

The companies’ exenatide 2 mg powder and solvent for prolonged release suspension for injection (proposed trade name Bydureon) has been recommended to be used as a once-weekly 2mg

The study matched the US medical records of 3,485 RLS patients to those of 3,485 patients without RLS. The most frequent CV diagnoses observed were hypertension (48%), cardiac

The placebo-controlled, double-blinded study equally divided 48 healthy subjects (31 female, 17 male; 39 ± 13 years of age) into two groups. One group consumed a placebo while

Alemtuzumab is a humanized monoclonal antibody used as a potential therapy to treat relapsing-remitting multiple sclerosis. In the trial, alemtuzumab was given to patients in two or three

reaZin, formerly named Zinthionein, is a proprietary, gastroretentive, sustained release, once-daily oral tablet formulated from zinc (150 mg) and cysteine (100 mg), an amino acid with potent anti-oxidant

Lapatinib is an oral small-molecule inhibitor of the EGFR and ErbB2 (HER2) tyrosine kinase receptors. The company seeks the approval for Tyverb as a treatment for the patients

Hyalofemme is a proprietary gel formulation of hyaluronate, a naturally occurring polysaccharide with moisturising and lubricating properties. Hyalofemme has been shown to be effective when used 3 times

The fingerprint technology discerns the so-called forensic ‘fingerprint’ of herbal medicine components using advanced techniques including chromatographic or spectral profiling. The profile can be used to identify different

Developed by Takeda, Edarbi is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure in adults. Edarbi may be used either